Aim: To investigate whether remission can be sustained for rheumatoid arthritis (RA) patients after tapering abatacept (ABT).
medication. [4] [5] [6] For these reasons, many studies investigated whether patients with remission or low disease activity with bDMARDs can maintain remission or low disease activity after discontinuation of bDMARDs. [7] [8] [9] [10] [11] However, withdrawal of biologics treatment has been associated with flare of RA disease activity and radiographic progression compared to continued treatment. [11] [12] [13] [14] [15] Hence, recent studies have focused on whether a reduced dose of bDMARDs could sustain remission, reducing the risk of infection and costs. [13] [14] [15] [16] [17] Previous studies reported that flare of disease activity was seen in 53%-88% of patients after tapering bDMARDs. 16, [18] [19] [20] However, these studies assessed the effects using different remission criteria, flare criteria, and observation periods. In addition,
factors that affect remission after tapering bDMARDs remain to be elucidated.
Abatacept, a selective co-stimulation modulator that inhibits Tcell activation, is available in subcutaneous (SC) and intravenous (IV)
formulations. Recently, clinical studies raise a possibility that ABT sustains remission after its withdrawal or tapering. 16, 17, [20] [21] [22] [23] However, there have been no data on tapering of ABT in which disease activity was assessed by ultrasound (US).
Ultrasound is a useful tool for diagnosis of RA, detection of joint inflammation, evaluation of the efficacy of RA treatment, and prediction of disease flare. [24] [25] [26] A recent study demonstrated that US can predict flare of RA disease activity after withdrawal of bDMARDs, mainly anti-tumor necrosis factor (anti-TNF) inhibitors. 27 However, the effect of tapering ABT on US findings is unclear.
The aim of this study was to determine whether sustained clinical and US remission of RA is possible with tapering of ABT.
| ME TH ODS

| Study population and design
This study is a prospective single-center study. All RA patients were diagnosed according to the American Rheumatism Association 1987 revised criteria for the classification of RA or the 2010
American College of Rheumatology/European League Against Rheumatism (EULAR) criteria for RA. 28, 29 All patients were older than 20 years, naïve to bDMARDs, failed at least one csDMARD, and had Disease Activity Score of 28 joints using C-reactive protein (DAS28-CRP) ≥2.3 but <4.1, body weight <60 kg, and anticyclic citrullinated peptide (ACCP) antibody ≥100 U/mL or rheumatoid factor (RF) ≥60 IU/mL. [30] [31] [32] The primary objective was to evaluate sustained remission after tapering of ABT therapy in patients with remission. In this study, remission was defined as DAS28-CRP <2.3. 33 In this study, we defined flare as non-remission. For the first 36 weeks, patients were administered SC ABT at 125 mg/wk or IV ABT at 500 mg every 4 weeks as remission induction therapy. For the patients who achieved remission and power Doppler (PD) score ≤1 at each joint, 34 ABT was tapered. 
| Efficacy assessments
Disease activity was evaluated at baseline and at 12, 24, 36 and 48 weeks after starting ABT therapy using DAS28-CRP. Using the DAS28-CRP scores, disease activity was classified as remission (<2.3), low (≤2.3 to <2.7), moderate (≤2.7 to <4.1), or high (≥4.1).
33
Physical function was assessed by the disability index of the Health Assessment Questionnaire (HAQ-DI). 35 With respect to demographic parameters, age, sex, disease duration, Steinbrocker stage and class, anti-CCP antibodies, and RF were assessed at baseline.
| Safety assessments
Safety was assessed at every visit. Safety assessments included measurement of vital signs and laboratory parameters, recording of adverse events, injection-site reactions, and resinous infections. were evaluated by a systematic multiplanar PD and gray-scale (GS) score examination. The PD and GS scores were graded on a semiquantitative scale from 0 to 3. The sums of the PD and GS scores of the 22 joints are expressed as the total PD score and total GS score. were considered statistically significant.
| US assessments
| Statistical analysis
| RESULTS
| Patients' baseline characteristics
Between April 2014 and March 2016, a total of 54 patients with RA participated in this study. Three patients were excluded for the following reasons: one patient had high disease activity; one was overweight (≥60 kg); and one was negative for CCP and RF. A total of 51 patients were followed for 48 weeks, and their baseline demographic data are shown in Table 1 . The mean age was 68.7 ± 10.2 years, mean disease duration was 7.7 ± 10.2 years, mean HAQ score was 0.80 ± 0.69, and mean DAS28-CRP was 3.66 ± 0.42. There were no significant differences in the demographic data at baseline between patients treated with SC ABT and those treated with IV ABT (Table 2 ).
| Efficacy of ABT treatment
One patient was withdrawn from the study because of lack of improvement. DAS28-CRP was significantly improved from 3.66 ± 0.42 at baseline to 2.52 ± 0.85 at 12 weeks, 2.45 ± 0.84 at 24 weeks, and 2.16 ± 0.85 at 36 weeks (P < 0.0001 at each time point) ( Figure 1A ). At 36 weeks, 29 patients achieved remission (Table 3) . Achievement of DAS28-CRP <2.3 in SC-administrated patients was significantly higher than that in IV-administrated patients (73.3% vs 33.3%, P = 0.009).
The total PD score was significantly improved from 11.4 ± 8.0 at baseline to 5.0 ± 5.2 at 24 weeks and 3.7 ± 3.6 at 36 weeks (P < 0.0001 at each time point) ( Figure 1B ). The total GS score was significantly improved from 15.7 ± 10.5 at baseline to 12.7 ± 7.7 at 24 weeks (P = 0.01) and 11.9 ± 8.1 at 36 weeks (P = 0.003) ( F I G U R E 1 Changes in disease activity. DAS28-CRP (A), total PD score (B), and total GS score (C). Last-observationcarried-forward analysis. Bars show 95% CIs. A, DAS28-CRP is significantly decreased at 12, 24, and 36 wk. *Indicates a significant difference compared with DAS28-CRP at baseline. B, The total PD score is significantly decreased at 24 and 36 wk. C, The total GS score is significantly decreased at 24 and 36 wk. *Indicates a significant difference compared at baseline. DAS28, Disease Activity Score of 28 joints; PD, power Doppler; GS, gray-scale
In the tapering group, the total PD scores were moderately worse from 1.52 ± 1.21 at 36 weeks to 2.59 ± 2.81 at 48 weeks (P = 0.049) ( Figure 2B ). Nine patients (31%) showed total PD scores ≥3 at 12 weeks after tapering. The total GS scores were not significantly elevated (9.2 ± 4.6 at 36 weeks vs 9.2 ± 4.8 at 48 weeks, P = 0.50) ( Figure 2C ). In the non-tapering group, the total PD scores were significantly improved from 6.5 ± 5.6 at 36 weeks to 5.3 ± 4.1 at 48 weeks (P = 0.022). The total GS scores were not significantly improved (15.1 ± 10.3 at 36 weeks vs 13.7 ± 6.6 at 48 weeks, P = 0.28).
| Factors for sustained ultrasound low disease activity
In the analysis of predictors of maintaining ultrasound low disease activity for 48 weeks, disease duration, DAS28-CRP, and total PD score at 24 weeks were correlated with the sustainability of low disease activity on univariate analysis (Table 4 ). In multiple logistic regression analysis, duration of disease was identified as independent predictors of sustain US low disease activity after tapering ABT (odds ratio, 0.71; 95% CI: 0.52-0.97; P = 0.001) ( Table 5 ).
| Safety of ABT therapy
No increased risk of adverse events including infection was observed for patients continuing or tapering ABT.
| DISCUSSION
The present study showed that, after tapering ABT, DAS28-CRP and total GS score were maintained stably, whereas the total PD score was significantly elevated. Longer disease duration, higher DAS28-CRP, and higher total PD score at 24 weeks were predictive factors for elevation of the total PD score. These results indicated that ABT tapering therapy can sustain remission, and US is useful for monitoring disease activity.
Recently, EULAR 3 has recommended that the therapeutic goal is remission or low disease activity, and the condition should be sustained, whereas intensive and continuous therapy with bDMARDs may result in adverse events, including serious infection, and high costs. A systematic review demonstrated that standard-dose or highdose bDMARDs were associated with an increased risk of serious infection compared with csDMARDs, but not low-dose bDMARDs. 38 Thus, the next goal of RA treatment should be to determine the optimal dose of bDMARDs.
Previous studies of de-escalation of bDMARDs reported mainly anti-TNF inhibitors. In the BeSt study, 8 
withdrawal of infliximab (IFX)
and csDMARDs could sustain remission in 18% of patients. Discontinued or tapering etanercept (ETN) was assessed for early and established RA. [13] [14] [15] In the randomized controlled PRESERVE trial, 13 patients were given 50 mg ETN plus methotrexate (MTX) every week, followed by administrating either ETN 25 mg plus MTX or placebo plus MTX. This study revealed that reduced ETN plus MTX maintained low disease activity more than single treatment with MTX. In the DOSERA study, 14 the percentage of flare patients with low disease activity was significantly lower with ETN 50 mg/wk and ETN 25 mg/wk than with placebo. These studies suggested that ETN dose reduction can result in sustained remission. Another study investigated whether stopping certolizumab pegol sustained remission, but only 3/17 patients maintained remission. 39 Nishimoto et al 11 investigated whether remission or low disease activity were maintained after discontinuation of tocilizumab (TCZ); the rate of sustained low disease activity at 52 weeks was 13.4%.
There are 6 studies analyzing the efficacy of withdrawal or reduction of ABT. 16, 17, [20] [21] [22] [23] Two studies stopped ABT, and four studies tapered ABT. In the Assessing Very Early Rheumatoid arthritis Treatment study, 21 patients with remission had withdrawal of all therapy including ABT. The reported flare rate was more than 70% after 6 months, defined as a 2-fold increase in swollen and tender joint counts, or an increase in DAS28 > 1.2, or based on physician assessment. Takeuchi et al 22 showed that flare rates in withdrawal of ABT therapy at 52 weeks were higher than those in continuous ABT therapy (41% vs 6%). Westhovens et al 16 reported that 34% of early RA patients with dose reduction of ABT to half-dose flared at 1 year. Also, changing the weekly SC administration of 125 mg ABT to biweekly administration was shown to deteriorate DAS28, suggesting that it is difficult to control disease activity with biweekly SC administration of ABT. 17 The MATADOR study, 23 with IV ABT dose reduction to 250 mg/body/mo after achievement of low disease activity, investigated whether ABT dose reduction therapy is a T A B L E 3 Baseline differences between patients who did or did not achieve remission after 36 wk | 85 feasible strategy for maintenance treatment. The remission rate at 12 months was 77%. These results indicated that maintaining remission is difficult if bDMARDs are withdrawn, but that tapering of bDMARDs can sustain remission. In these studies, definitions of remission or flare, patient enrolment, and observation periods (12 weeks to 7 years) were different, [7] [8] [9] [10] [11] 27 and more studies are needed. In the present study, 86.2% of patients sustained remission after tapering ABT therapy. The rate of sustained remission in the present study was higher than in previous reports; the reason for this is considered to be the shorter observation period and patient entry bias.
A previous study demonstrated that the lower levels of DAS28 at baseline, particularly deep remission, 9 predicted sustained remission or low disease activity after tapering bDMARDs. In the present study, disease activity was also evaluated by US during ABT tapering. Previous studies found that synovitis was detected by US in half of RA patients who reached clinical remission, 40, 41 suggesting that US could detect small changes in RA disease activity more sensitively than clinical examination. Also, US is reported to be a useful tool to identify flare after withdrawal or reduction of bDMARDs. 42, 43 In the POET study, 42 patients with low disease activity with US-detected arthritis in one or more joints had a risk of flare after discontinuation compared to patients without such signs. Alivemini et al investigated whether clinical and US remission could identify patients suitable for proceeding to reduction of anti-F I G U R E 2 Change in disease activity after tapering ABT therapy. DAS28-CRP (A), total PD score (B), and total GS score (C). A, DAS28-CRP is not changed after tapering ABT. B, The total PD score is significantly elevated after tapering ABT (P = 0.049). C, The total GS core is not changed after tapering ABT. ABT, abatacept; DAS28, Disease Activity Score of 28 joints; PD, power doppler; GS, grayscale TNF inhibitor therapy after achievement of remission. 42 In 42
patients tapering an anti-TNF inhibitor, 30.9% relapsed after 3 months. Patients with higher synovial hypertrophy at the 2nd MCP and 5th MTP joints were more likely to relapse, suggesting that US is a useful tool to predict relapse after tapering anti-TNF inhibitors. Another study 44 suggested that the presence of a PD signal was a predictive factor for bDMARDs tapering failure, including 2 patients on ABT. Iwamoto et al 37 showed that higher total GS and PD scores by US were significantly strong predictors of relapse after withdrawal of bDMARDs (anti-TNF inhibitors or TCZ) in 42 RA patients, who achieved remission by combination bDMARDs and MTX. On the other hand, little is known about the utility of US-based evaluation in ABT tapering therapy. 44 The present study showed that ABT tapering therapy did not alter DAS28-CRP, but the total PD score was significantly elevated, particularly in patients with long disease duration and higher disease activity at seronegative patients. 45, 46 Third, the observation period may be short. In previous studies, the observation periods ranged from 12 weeks to over 7 years for assessing withdrawal or tapering of drugs. Longer observation than 12 weeks may be required to confirm the results. Fourth, there is no established US remission criteria evaluating 22 joints. We defined US low disease activity criteria as the total PD score <3. 37 Other US remission criteria also should be examined.
The findings of the present study suggest that ABT tapering therapy is a short-term strategy for RA patients who achieve remission, particularly in those with shorter disease duration and long sustained remission, and US is a useful tool to identify disease activity flare.
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